![]() Brennan commented, "It has been a privilege to serve as President & CEO of NervGen over the past three years, working hand in hand with a strong dedicated team, the company's Board of Directors, and our scientific founder, Dr. We look forward to working with him during this transition period and wish him the best in his future endeavors." With a Phase 1 safety study actively enrolling patients, multiple Phase 2 clinical trials in development with anticipated readouts beginning in 2024 and a cash balance of $25 million, the largest in the company's history, Paul has helped position NervGen to become a leading player in the emerging central nervous system repair field. "Under Paul's leadership, NervGen has evolved from a pre-clinical company focused primarily on spinal cord injury to a clinical company with three active clinical development programs underway focused more broadly on repairing nervous system damage from both traumatic injuries and neurodegenerative disease. "On behalf of the Board of Directors and shareholders of NervGen, I would like to thank Paul for his hard work and many contributions to NervGen over the past three years," said Mr. Radvak received a Bachelor of Applied Science degree from the University of British Columbia. He was a founder and the CEO of Response Biomedical, a publicly listed medical device company that he led from inception into a sales and manufacturing company. Radvak has been the CEO and director of multiple start-up companies. Radvak served as President of NervGen from January 2017 to June 2018. The Board has initiated a search for a permanent CEO. Brennan will serve as a strategic advisor to management and the Board during the transition period. The Board of Directors has appointed current Executive Chairman of the Board Bill Radvak as interim CEO and current Board member Dr. Brennan will step down as President & Chief Executive Officer and a member of the Board, effective immediately. (OTCQX: NGENF) (TSXV: NGEN), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced today that the Board of Directors and Paul Brennan have mutually agreed that Mr. September 22, 2022) - NervGen Pharma Corp. Vancouver, British Columbia-(Newsfile Corp. Paul Brennan to step down as President & Chief Executive Officer and member of the Board of Directors will serve as a strategic advisor for a transition period.Adam Rogers, member of the Board of Directors, appointed interim President Bill Radvak, Co-founder and Executive Chairman of the Board, appointed interim Chief Executive Officer. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |